Matthew Simpson, Co-chair of Mintz’s Private Equity Practice, has been selected to receive the Distinguished Alumni Award on behalf of the International Trade and Investment Law Society (ITILS) at the American University Washington College of Law. This award honors his contributions to the establishment of ITILS and his continued career successes.

Mintz is advising Berenson & Company, LLC in a merger agreement between Getty Images Holdings, Inc. (NYSE: GETY) and Shutterstock (NYSE: SSTK). The combined company would have an enterprise value of approximately $3.7 billion. Additional information is available here. The Mintz team is led by Ivan Presant and Matthew T. Simpson with support from Jason Miller and Doug Baumstein.

Private Equity Co-chair Matt Simpson was featured along with other Private Equity leaders in Mergers & Acquisition's 2025 M&A Outlook. Matt provided his predictions for the space in the upcoming year. 

Private Equity Co-Chair Matthew T. Simpson spoke with Private Equity International on trends in private equity and the potential implications for mid-market private equity sponsors.

Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.

Private Equity managers are facing challenges such as a downturn in private market valuations and difficulties in securing affordable debt for new deals. Private Equity Co-chair Matthew T. Simpson provided insights on the market to PitchBook, discussing strategies PE sponsors are expected to adopt in 2024 to optimize results.

Senior VP of ML Strategies John Lushetsky, Private Equity Co-chair Matthew T. Simpson, Member Paul H. Dickerson, and Raj Gambhir co-authored an article in Law360 discussing the collaborative efforts between the US and Canada in the development of critical mineral and semiconductor supply chains.

Reorg recently discussed the impact of higher interest rates on the deal making environment and market sentiment for the upcoming year with Private Equity Co-chair Matthew T. Simpson.

GPs, particularly those in the lower middle market, leverage co-investments to forge and strengthen relationships with LPs — an otherwise challenging feat given the current slow-paced fundraising climate. In a PitchBook article, Private Equity Practice Co-chair Matthew T. Simpson explores the strategic utilization of co-investments by smaller private equity firms.

WASHINGTON, DC – Mintz served as legal counsel to Invited, Inc. in its sale of certain assets related to its BigShots Golf business to Topgolf Callaway Brands Corp.

Private equity firms are buying strong businesses while using less or deferred debt, and expanding existing portfolio companies through bolt-on and add-on acquisitions. Mintz’s Private Equity Co-chair Matthew T. Simpson outlined the benefits of lower-leverage transactions and other dealmaking trends to Mergers & Acquisitions.

Co-chair of Mintz's Private Equity Practice, Matthew T. Simpson spoke to PitchBook and discussed the rise of add-on/bolt-on acquisitions for private equity sponsors.

WASHINGTON, D.C. – Mintz’s Private Equity Co-Chair, Matthew T. Simpson is one of a group of experts arranged by the Public International Law & Policy Group (PILPG) to develop a series of tools and resources to assist with potential future ceasefire negotiations between Ukraine and Russia.

Mintz represented ArriVent Biopharma in a $155 Million Series B financing led by Sofinnova Investments and General Catalyst to fund studies of the company's EGFR kinase inhibitor furmonertinib. Members Ed Pease and Private Equity Practice Co-Chair Matthew Simpson led the Mintz team's work on the transaction.

BOSTON – Mintz has served as legal counsel to wealth-management firm Lido Advisors LLC, a Charlesbank Capital Partners portfolio company, in its partnership with Colorado Financial Management (CFM).

Mintz Private Equity Practice Co-chair Matthew Simpson spoke to Middle Market Growth for a special report on the 2023 outlook for M&A deal activity and private equity transactions. He commented on the decline of so-called “walkaway deals,” where sellers are subject to long-term exit conditions.

Mintz Private Equity Practice Co-chair Matthew Simpson spoke to Middle Market Growth for a special report on the 2023 outlook for M&A deal activity and private equity transactions. He commented on the decline of so-called “walkaway deals,” where sellers are subject to long-term exit conditions.

Members Gregory Fine, Matthew T. Simpson and Kurt Steinkrauss were featured in an article published by The Deal highlighting their appointment to co-lead the Firm's Private Equity practice.

Mintz has appointed Members Gregory Fine and Matthew T. Simpson to co-lead the Private Equity practice alongside current chair, Kurt Steinkrauss. The change is effective immediately.

Mintz attorneys in Boston, New York, and Washington, DC, closed four Private Equity transactions in the past month. Along with acquisitions for Charlesbank Capital Partners, DIF Capital Partners portfolio company Joink LLC, and Artemis Capital Partners, the firm represented the CEO and some managers of Salary.com in the sale of most of the company’s equity interests to Accel-KKR.

Mintz Private Equity Member Matthew Simpson spoke to Fierce Healthcare about the heightened antitrust scrutiny of private equity deals in the health sector by both the FTC and DOJ. He also discussed how sponsors can adapt to this shift in enforcement priorities and what it means for the health sector. 

Mintz's interdisciplinary team continues its leadership role in life sciences, serving as legal counsel to ProKidney LP in its $2.6 billion SPAC merger, and its subsequent listing on the Nasdaq under the ticker symbol "PROK". ProKidney is a leading clinical-stage cellular therapeutics company focused on chronic kidney disease. ProKidney's lead product candidate is in Phase 3 clinical development and has the potential to slow, stabilize and reverse decline in kidney function

The deal will take public ProKidney, a leading clinical-stage cellular therapeutics company focused on chronic kidney disease, and is expected to provide up to $825 million in gross cash proceeds.